Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ABILITY-1 study, showcasing significant single-agent activity of MDNA11 in patients with advanced solid tumors. The study also highlights a favorable safety profile when MDNA11 is combined with KEYTRUDA, indicating potential for enhanced cancer treatment options. These developments are promising for investors watching the biotech sector.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.